In 2025, the Company delivered another year of strong growth and materially improved profitability. Revenue rose 35.1% year-over-year to RMB 1.06 billion, while net profit increased 143.7% year-over-year to RMB 244 million. Growth was driven by continued commercial momentum across core products, rapid growth in international business, and further improvement in operating efficiency.
The Company's neurovascular intervention business generated revenue of RMB 676 million, up 28.0% year-over-year, while revenue from peripheral vascular intervention increased 50.3% year-over-year to RMB 379 million. Revenue from markets outside Mainland China reached RMB 48.65 million, up 115.5% year-over-year, reflecting continued progress in international market access and channel expansion.
Despite the continued impact of volume-based procurement in China, Zylox-Tonbridge maintained a gross margin of 72.1% in 2025 and reported non-IFRS adjusted net profit of RMB 273 million, reflecting improving operating leverage as the business scaled. As of the end of the reporting period, total available financial resources, including cash and cash equivalents, term deposits and financial assets measured at fair value through profit or loss, amounted to RMB 2.60 billion.
Supported by ...
